CD274 and neoplasm: Nonetheless, studies about immune checkpoint inhibitors have demonstrated significant improvements in the outcomes of patients with locally advanced or metastatic HNSCCs, and PD-L1 expression by tumor and immune cells still accounts for the main predictive biomarker of good response [36].